Want to see JP:4552 full AI Analyst Report?

JCR Pharmaceuticals Co., Ltd. (4552) Price & Analysis

1 Followers

4552 Stock Chart & Stats

¥712.00

-¥21.00(-3.43%)

At close: Jan 08 4:00 PM EST

¥712.00

-¥21.00(-3.43%)

Day’s Range― - ―

52-Week Range¥444.00 - ¥824.00

Previous CloseN/A

Volume326.50K

Average Volume (3M)869.54K

Market Cap

¥67.32B

Enterprise Value¥115.01B

Total Cash (Recent Filing)¥9.66B

Total Debt (Recent Filing)¥53.94B

Price to Earnings (P/E)―

Beta0.87

Next Earnings

Jan 28, 2027

EPS Estimate

-13.83

Next Dividend Ex-DateN/A

Dividend Yield3.68%

Share Statistics

EPS (TTM)6.72

Shares Outstanding129,686,310

10 Day Avg. Volume836,830

30 Day Avg. Volume869,543

Financial Highlights & Ratios

PEG Ratio-0.22

Price to Book (P/B)1.48

Price to Sales (P/S)1.72

P/FCF Ratio-5.99

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

¥766.67

Price Target Upside7.68% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

EPS Forecast (FY)2.4

Revenue Forecast (FY)¥45.66B

Bulls Say, Bears Say

Bulls Say

Specialty Biopharmaceutical FocusA focus on rare and intractable diseases gives JCR a specialized business model centered on biologics and prescription therapies. This orientation can support differentiated product development and recurring demand where treatment options are medically important, although product success remains dependent on execution.

FY2026 Revenue RecoveryThe FY2026 revenue rebound demonstrates that the business can recover sales after a major setback and regain commercial momentum. If sustained through additional product demand and market activity, stronger revenue provides a broader base for absorbing fixed costs and rebuilding earnings power.

Strong Gross Profit BaseConsistently strong gross profit indicates that JCR’s marketed products and specialty pharmaceutical activities retain meaningful economic value before operating expenses. This provides a foundation for future profitability improvement if revenue growth persists and the company controls spending and investment intensity.

Bears Say

Persistent Cash BurnRecent operating and free cash flow weakness means the business is not currently funding its activities reliably from internal cash generation. Continued cash burn can increase reliance on financing, constrain investment choices, and raise execution risk while management works to restore sustainable inflows.

Higher LeverageA materially higher debt load increases the company’s financial obligations while recent cash generation is weak. This combination leaves less flexibility to fund research, manufacturing, or commercialization internally and makes the balance sheet more sensitive to any renewed softness in profitability.

Volatile ProfitabilityLarge swings in operating results weaken confidence in near-term earnings durability. The return to profit in FY2026 is encouraging, but thin operating profitability after a substantial loss suggests that revenue recovery has not yet translated into a stable earnings base capable of supporting cash generation.

JCR Pharmaceuticals Co., Ltd. News

JCR Pharmaceuticals Issues FY2026 Q2 Results Briefing with Caution on Projections

The latest update is out from JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ). JCR Pharmaceuticals has released materials...

3d ago

4552

JCR Pharmaceuticals Swings to Interim Loss but Keeps Dividend and Full-Year Outlook

The latest announcement is out from JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ). JCR Pharmaceuticals reported consolidated net...

3d ago

4552

Italfarmaco Secures Exclusive Rights to JCR’s Hunter Syndrome Therapy JR-141 in Key Global Markets

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) has shared an update. Italfarmaco S.p.A. and JCR Pharmaceuticals have signed...

30d ago

4552

JCR Pharmaceuticals Deepens Fucosidosis Research With New Long-Term Patient Study

JCR Pharmaceuticals Co., Ltd. ($JP:4552) announced an update on their ongoing clinical study. The study A Retrospective and...

3M ago

4552

JCR Pharmaceuticals Posts Wider Quarterly Loss but Keeps Earnings and Dividend Outlook Intact

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) has provided an announcement. JCR Pharmaceuticals reported first-quarter FY2026 consolidated net...

3M ago

4552

JCR Pharmaceuticals Releases FY2026 Q1 Briefing Materials With Key Investor Disclaimers

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) has shared an update. JCR Pharmaceuticals has released materials for its...

3M ago

4552

JCR Pharmaceuticals Completes Restricted Stock Compensation Transaction

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) has provided an update. JCR Pharmaceuticals has completed the payment procedures...

3M ago

4552

JCR Pharmaceuticals Sets 2026–2027 Timeline to Launch Givinostat for Duchenne Muscular Dystrophy in Japan

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) just unveiled an update. JCR Pharmaceuticals announced a development plan to...

4M ago

4552

JCR Pharmaceuticals Corrects FY2025 Results as Profit Rebounds and Dividend Held Steady

An update from JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) is now available. JCR Pharmaceuticals has announced partial...

4M ago

4552

JCR Pharmaceuticals Corrects FY2024 Results as Weak Performance Prompts Closer Scrutiny

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) has issued an announcement. JCR Pharmaceuticals has issued a partial correction...

4M ago

4552

4552 FAQ

What was JCR Pharmaceuticals Co., Ltd.’s price range in the past 12 months?

JCR Pharmaceuticals Co., Ltd. lowest stock price was ¥444.00 and its highest was ¥824.00 in the past 12 months.

What is JCR Pharmaceuticals Co., Ltd.’s market cap?

JCR Pharmaceuticals Co., Ltd.’s market cap is ¥67.32B.

When is JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date?

JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date is Jan 28, 2027 which is in 89 days.

How were JCR Pharmaceuticals Co., Ltd.’s earnings last quarter?

JCR Pharmaceuticals Co., Ltd. released its earnings results on Oct 29, 2026. The company reported -¥16.03 earnings per share for the quarter, missing the consensus estimate of ¥0.168 by -¥16.198.

Is JCR Pharmaceuticals Co., Ltd. overvalued?

According to Wall Street analysts JCR Pharmaceuticals Co., Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does JCR Pharmaceuticals Co., Ltd. pay dividends?

JCR Pharmaceuticals Co., Ltd. pays a Semiannually dividend of ¥10 which represents an annual dividend yield of 3.68%. See more information on JCR Pharmaceuticals Co., Ltd. dividends here

What is JCR Pharmaceuticals Co., Ltd.’s EPS estimate?

JCR Pharmaceuticals Co., Ltd.’s EPS estimate is -13.83.

How many shares outstanding does JCR Pharmaceuticals Co., Ltd. have?

JCR Pharmaceuticals Co., Ltd. has 129,686,310 shares outstanding.

What happened to JCR Pharmaceuticals Co., Ltd.’s price movement after its last earnings report?

JCR Pharmaceuticals Co., Ltd. reported an EPS of -¥16.03 in its last earnings report, missing expectations of ¥0.168. Following the earnings report the stock price went down -0.195%.

Which hedge fund is a major shareholder of JCR Pharmaceuticals Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4552

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. is a specialized pharmaceutical firm primarily engaged in the creation, development, manufacturing, international trade, and distribution of medicinal products, regenerative therapies, and active pharmaceutical ingredients within Japan. The company offers a range of therapeutic solutions, including GROWJECT, which addresses growth hormone deficiency and short stature; IZCARGO, prescribed for Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion, utilized in the management of Fabry disease; and TEMCELL HS Inj, employed to treat acute graft-versus-host disease. Beyond its current offerings, JCR Pharmaceuticals is also developing Epoetin Alfa BS and Darbepoetin Alfa BS Injections, both intended for the treatment of renal anemia. Furthermore, the company markets various medical devices and laboratory instruments. Founded in 1975, its headquarters are situated in Ashiya, Japan.

JCR Pharmaceuticals Co., Ltd. (4552) Earnings & Revenues

Historic Earnings Reports

4552 Stock 12 Month Forecast

Average Price Target

¥766.67

▲(7.68% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"446":"¥446","1201":"¥1,201","634.75":"¥634.8","823.5":"¥823.5","1012.25":"¥1,012.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥1.20K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":766.6666666666666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥766.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":540,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥540.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[446,634.75,823.5,1012.25,1201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,502,555.6923076923077,609.3846153846154,663.0769230769231,716.7692307692307,770.4615384615385,824.1538461538462,877.8461538461538,931.5384615384615,985.2307692307693,1038.923076923077,1092.6153846153848,1146.3076923076924,{"y":1200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,502,522.3589743589744,542.7179487179487,563.0769230769231,583.4358974358975,603.7948717948718,624.1538461538462,644.5128205128206,664.8717948717949,685.2307692307693,705.5897435897436,725.9487179487179,746.3076923076923,{"y":766.6666666666666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,502,504.9230769230769,507.84615384615387,510.7692307692308,513.6923076923077,516.6153846153846,519.5384615384615,522.4615384615385,525.3846153846154,528.3076923076923,531.2307692307693,534.1538461538462,537.0769230769231,{"y":540,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":611.25,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":576.542,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":734.657,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":686.451,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":584.255,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":636.317,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":582.375,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":532.373,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":455.9,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":447.076,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":469.626,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":527.471,"date":1788220800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":502,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >